

# Midterm procedural and clinical outcomes of percutaneous paravalvular leak closure with the Occlutech Paravalvular Leak Device



**Eustaquio Maria Onorato**<sup>1\*</sup>, MD; Manuela Muratori<sup>1</sup>, MD; Grzegorz Smolka<sup>2</sup>, MD, PhD; Magdalena Malczewska<sup>3</sup>, MD; Aleksejus Zorinas<sup>4</sup>, MD, PhD; Diana Zakarkaite<sup>4</sup>, MD; Abdurashid Mussayev<sup>5</sup>, MD; Christous P. Christos<sup>6</sup>, MD; Fabrice Bauer<sup>7</sup>, MD; Thomas Gandet<sup>8</sup>, MD; Gian Luca Martinelli<sup>9</sup>, MD; Anna Maria Costante<sup>10</sup>, MD; Antonio L. Bartorelli<sup>11</sup>, MD

1. Centro Cardiologico Monzino, IRCCS, University School of Milan, Milan, Italy; 2. 3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland; 3. Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University, Katowice, Poland; 4. Department of Cardiovascular Medicine, Vilnius University, Vilnius, Lithuania; 5. National Research Cardiac Surgery Center, Astana, Kazakhstan; 6. American Heart Institute, Nicosia, Cyprus; 7. Centre Hospitalier Universitaire "Charles Nicolle", Rouen, France; 8. Centre Hospitalier Universitaire, Hôpital Arnaud de Villeneuve, Montpellier, France; 9. Clinica San Gaudenzio, Novara, Italy; 10. Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; 11. Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy

This paper also includes supplementary data published online at: <https://eurointervention.pconline.com/doi/10.4244/EIJ-D-19-00517>

## KEYWORDS

- imaging modalities
- specific closure device/technique
- transoesophageal echocardiogram
- transthoracic echocardiogram


## Abstract

**Aims:** The aim of this study was to assess the efficacy and safety of the Occlutech Paravalvular Leak Device (PLD) for the percutaneous closure of paravalvular leaks (PVL).

**Methods and results:** Patients with PVL were enrolled at 21 sites from nine countries. Indications for PVL closure were heart failure and/or haemolytic anaemia. Endpoint measures were changes in PV regurgitation grade, NYHA class and requirement for haemolysis-related transfusion. One-hundred and thirty-six patients with mitral (67.6%) or aortic (32.4%) leaks were included (mean age 66.7 years, 58% male); 31% had multiple PVLs. The proportion of patients with NYHA Class III/IV decreased from 77.3% at baseline to 16.9% at latest follow-up. The proportion of patients with need for haemolysis-related blood transfusion decreased from 36.8% to 5.9% and from 8.3% to 0% for ML patients and AL patients, respectively. All-cause mortality was 7.4%. Complications included interference with valve leaflets (0.7%), transient device embolisation (percutaneously solved) (0.7%), late device embolisation (0.7%), recurrent haemolytic anaemia (2.2%), new-onset haemolytic anaemia (0.7%), valve surgery (2.2%), need for repeat closure (0.7%), complications at femoral puncture site (0.7%) and arrhythmias requiring treatment (4.4%).

**Conclusions:** PVL closure with the Occlutech PLD demonstrated a high success rate associated with significant clinical improvement and a relatively low rate of serious complications.

\*Corresponding author: Centro Cardiologico Monzino, IRCCS, University School of Milan, Via C. Parea, 4, 20138 Milan, Italy.  
E-mail: [eustaquio.onorato@gmail.com](mailto:eustaquio.onorato@gmail.com)



## Abbreviations

<b>AE</b>	adverse events
<b>ECG</b>	electrocardiography
<b>GA</b>	general anaesthesia
<b>IFU</b>	instructions for use
<b>LDH</b>	lactate dehydrogenase
<b>LVEF</b>	left ventricular ejection fraction
<b>NT-proBNP</b>	N-terminal pro-brain natriuretic peptide
<b>NYHA</b>	New York Heart Association
<b>PLD</b>	paravalvular leak device
<b>PVL</b>	paravalvular leak
<b>SD</b>	standard deviation
<b>TEE</b>	transoesophageal echocardiography
<b>TTE</b>	transthoracic echocardiography

## Introduction

Transcatheter closure of paravalvular leak (PVL), first described in 1992<sup>1</sup>, has slowly evolved into a viable and less invasive alternative to surgery in high-risk patients with suitable anatomy<sup>2-4</sup>. Complete PVL sealing is relatively rare due to irregular leak morphology and the complex anatomy of the surrounding tissue. This creates the need for dedicated devices ideally available in multiple sizes and shapes for improving procedural efficacy and success. The Occlutech Paravalvular Leak Device (PLD) (Occlutech, Helsingborg, Sweden) is the only device specifically designed and certified in Europe (CE marked in 2014) for the treatment of mitral leaks (ML) and aortic leaks (AL). This international, multicentre registry was designed to provide additional clinical data on the efficacy and safety of the


PLD in high-risk patients with ML or AL after surgical implantation of prosthetic heart valves.

## Methods

This registry considered PLD closure procedures performed in 21 hospitals in nine EU and non-EU countries (**Supplementary Appendix 1**). All centres were contacted to participate in this study, and all agreed to participate. Anonymised data were acquired from medical and electronic records regarding patient medical history, demographics, vital signs, clinical laboratory tests, 12-lead electrocardiography (ECG) and transthoracic and transoesophageal echocardiography (TTE/TEE). Signed informed consent was obtained from all patients prior to the procedure. The study plan was approved by an independent ethics committee, the International Medical and Dental Ethics Commission (IMDEC).


## PROCEDURE

Two- and three-dimensional (2D/3D) TEE was used throughout each procedure, particularly in ML for complete and accurate delineation of these defects (**Figure 1, Figure 2, Moving image 1-Moving image 6**). Three-dimensional modalities included real-time 3D zoom and full volume acquisition with and without colour flow imaging. The degree of valvular regurgitation was evaluated by Doppler echocardiography using the guidelines recommended by the American Society of Echocardiography<sup>5</sup>. In some cases, ECG-gated cardiac computed tomography (CT) angiography was employed to define the location, size, shape and trajectory of PVL.



**Figure 1.** Echocardiographic (A-F) and fluoroscopic imaging (G-J) of transcatheter closure of a posterolateral, crescent-shaped mitral PVL with severe regurgitation in a patient with a bileaflet mechanical valve prosthesis. A) 2D TEE colour Doppler showing the regurgitant leak (arrowhead). B) 3D TEE colour Doppler image cropped at the level of the vena contracta clearly identified the single mitral paraprosthetic leak at 8 o'clock (arrowhead). C) 3D TEE showing the posterolateral defect (arrowhead). D) The wire crossing the PVL hole (arrowhead) seen on 3D TEE images. E) Post-procedure 2D TEE colour Doppler demonstrating no residual regurgitant leak. F) Final position of a 12×5 mm rectangular twist PLD (arrowhead) on 3D TEE. G) Fluoroscopic imaging showing a 5 Fr multipurpose catheter (arrow) and an exchange wire (arrowhead) crossing the mitral leak. H) Opening of the distal disc (arrowhead) of the occluder. I) Opening of the waist and the proximal disc (arrowhead) of the occluder. J) Full deployment of the 12×5 mm rectangular twist PLD (arrowhead) after delivery cable detachment.

Patients with a moderate-to-severe PVL causing heart failure and/or haemolysis with the need for recurrent blood transfusions who were deemed high risk for surgery by the Heart Team were considered for closure. Patients were treated according to the



**Figure 2.** 2D colour Doppler and 3D TEE images before (A-C) and after (D-F) percutaneous closure of a crescent-shaped, posterolateral (7 o'clock) paravalvular mitral leak in a patient with a mechanical Starr-Edwards caged-ball prosthetic valve (arrowhead) and a mechanical aortic valve (arrow) + dual-chamber pacemaker. Fluoroscopic images (G-J) show the implantation steps of a 10×4 mm rectangular waist PLD.

device instructions for use (IFU) and standard clinical practice. Procedures were performed under general anaesthesia (GA) or conscious sedation due to the need for intraprocedural TEE guidance. In a subset of patients, transapical catheter-based mitral PVL closure procedures were performed with a fusion of real-time 3D TEE and cardiac fluoroscopy imaging<sup>6</sup>.

### THE OCCLUTECH PLD

The Occlutech PLD is a self-expanding, flexible, double-disc device made from nitinol-braided wires that has been specifically engineered combining and improving several features of previous off-label devices. Two different disc geometries are available, square and rectangular, connected by a waist of different sizes and shapes to improve stability and minimise the erosion risk of the surrounding tissue<sup>7,8</sup>.

## STATISTICAL ANALYSIS

All statistical analyses were performed by means of commonly applied descriptive statistics. The study does not allow any confirmatory analyses. The analysis comprises the safety data of 136 patients. Baseline and six-month follow-up analyses consider data from 106 patients. Categorical variables are presented as numbers and percentages. Continuous variables are expressed as mean±standard deviation (SD) or median and interquartile range. Differences compared to baseline were assessed using a one-sample t-test for normally distributed variables. The Wilcoxon signed-rank test was used for non-normally distributed variables. Categorical variables were compared by the Wilcoxon signed-rank test. Two-sided p-values <0.05 were considered statistically significant in all analyses. All calculations were carried out with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

## Results

A total of 179 PLDs were implanted in 136 consecutive patients in 21 centres in nine countries (December 2014–February 2018). Safety data were collected from 136 patients. Baseline and six-month follow-up data from 106 patients (69 mitral and 37 aortic) are considered in the following analyses, if not mentioned otherwise. The average patient follow-up time was 153.8±80 days.

## BASELINE CHARACTERISTICS

Demographic and clinical data for patients with ML and AL are summarised in **Table 1**. Mean patient age was 66.2 years (min: 26, max: 84), 58.1% were male and 78.9% presented in NYHA Class III/IV. Main indications were heart failure (49.3%), haemolytic anaemia (4.8%), or both (43%). Twenty-five (36.8%) of the ML and three (8.3%) of the AL patients were dependent on blood transfusions.

## PROCEDURAL DETAILS

**Table 2** shows procedural details. ML were approached under GA (62.5%) and 3D TEE guidance (63.1%) via surgical transapical (“hybrid approach”) (66.7%), antegrade transseptal (30.0%) or retrograde transaortic from the left ventricle (3.3%). In 20.6% of AL patients, PLD were implanted under GA and leaks were always accessed via a retrograde transaortic approach (100%). In 36.2% and 21.6% of ML and AL patients, respectively, multiple leaks were treated. Most ML and AL were closed with one PLD per leak (79.4% and 75.6%, respectively). In several patients, the number of PLD used was less than the number of leaks (10.3% in ML patients and 18.9% in AL patients). In most cases, rectangular waist shape PLD were used followed by the rectangular twist shape (**Figure 3**). Median procedural time for ML closure was 122.5 (110-135) minutes in transapical cases and 62.5 (48-125) minutes in transseptal cases. Median fluoroscopy time was not significantly different between the two access routes (20.5 vs 25 minutes). Median procedural and fluoroscopy times for AL closure were 90 (70-110) and 15 (11-24) minutes, respectively.

**Table 1. Baseline characteristics.**

		Mitral, N=69*	Aortic, N=37*
Age, years		66.7±8.3	65.1±14.2
Weight (m), kg		78.1±10.9	77.8±11.1
Weight (f), kg		69.6±16.1	75.6±9.4
Height (m), cm		176.5±7.4	172.6±7.6
Height (f), cm		162.7±6.8	167.2±7.7
Male gender		30 (43.5%)	31 (83.8%)
Pulse rate, bpm		77.6±9.3	72.4±9.1
Systolic blood pressure, mmHg		124.7±16.7	130.4±14.4
Diastolic blood pressure, mmHg		71.5±9.8	68.6±9.6
LVEF, %		49.3±9.3	49.8±11.1
PV regurgitation grade	Small	1 (1.4%)	0 (0.0%)
	Moderate	1 (1.4%)	3 (8.1%)
	Severe	67 (97.1%)	34 (91.9%)
NYHA Class	I	1 (1.5%)	1 (2.8%)
	II	8 (11.8%)	12 (33.3%)
	III	42 (61.8%)	19 (52.8%)
	IV	17 (25.0%)	4 (11.1%)
Transfusion requirement		25 (36.8%)	3 (8.3%)
Indication	Heart failure	41 (49.3%)	
	Haemolytic anaemia	4 (4.8%)	
	Heart failure + haemolytic anaemia	36 (43%)	
Laboratory values	LDH, U/l #	607.0±627.8; (N=47)	
	Erythrocytes, Mio/μl #	4.1±0.7; (N=73)	
	Thrombocytes, Thsd/μl #	196.5±62.5; (N=75)	
	Leucocytes, /μl #	6,698.1±1,929.5; (N=73)	
	Haemoglobin, mmol/l #	7.6±1.4; (N=75)	
	NT-proBNP, pg/ml #	1,611.2±2,680.2; (N=35)	

Values are N (%) or mean ±SD. \*The numbers may not add up to the column totals and the percentages may not add up to 100% because of missing data. Except for laboratory values, in this table continuous data are given with at least 83.3% evaluable data points. # Baseline laboratory values are presented unstratified for leak type. N is given per value. LDH: lactate dehydrogenase; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA: New York Heart Association

## LEAK CHARACTERISTICS

**Table 3** presents details of the anatomical characteristics and number of PLD used in 131 ML and 53 AL patients. More than 80% of PVL had a maximum diameter of <10 mm and either a crescent or oval shape. ML were located posteriorly in 35.9% of the cases and in a medial position in 29%. Most AL were located in the non-coronary sinus area (55.8%). Intraprocedural TEE showed severe PV regurgitation in 97.1%, moderate in 81.4% and small in 1.4% of ML patients, and severe in 91.9% and moderate in 8% of AL patients.

## OUTCOMES

At follow-up, paravalvular regurgitation was severe in 4.5%, moderate in 7.6%, small in 56.1% and absent in 31.8% in ML patients. In AL patients, it was severe in 2.7%, moderate in

**Table 2. Procedural details.**

		Mitral, N=69*	Aortic, N=37*
General anaesthesia		40 (62.5%)	7 (20.6%)
Visualisation	TEE	22 (33.8%)	24 (66.7%)
	TTE	1 (1.5%)	0 (0.0%)
	TEE+TTE	0 (0.0%)	1 (2.8%)
	TEE+3D	41 (63.1%)	10 (27.8%)
	TEE+TTE+3D	1 (1.5%)	1 (2.8%)
Approach	Transseptal	18 (30.0%)	0 (0.0%)
	Transaortic	2 (3.3%)	35 (100%)
	Transapical	40 (66.7%)	0 (0.0%)
Number of leaks	1	44 (63.8%)	29 (78.4%)
	2	20 (29.0%)	8 (21.6%)
	3	5 (7.2%)	0 (0.0%)
PLDs implanted	1	45 (66.2%)	34 (91.9%)
	2	16 (23.5%)	3 (8.1%)
	3	5 (7.4%)	0 (0.0%)
Patient/device ratio	Devices=leaks	54 (79.4%)	28 (75.6%)
	Devices <leaks	7 (10.3%)	7 (18.9%)
	Devices >leaks	7 (10.3%)	2 (5.4%)
PLD type used <sup>y</sup>	Square waist	10 (12.3%)	2 (5.3%)
	Square twist	9 (11.1%)	1 (2.6%)
	Rectangular waist	49 (60.5%)	29 (76.3%)
	Rectangular twist	13 (16.0%)	6 (15.8%)
Procedural time by approach, min	Transseptal	62.5 (48, 125)	n.a.
	Transaortic	90.0 (70, 110)	90 (70, 110)
	Transapical	122.5 (110, 135)	n.a.
Fluoroscopy time by approach, min	Transseptal	25.0 (19, 38)	n.a.
	Transaortic	14.0 (14, 14)	15 (11, 24)
	Transapical	20.5 (15, 34)	n.a.
Procedural time by no. of leaks, min	1	70.0 (45, 120)	90 (70, 115)
	2	110.0 (90, 175)	95 (75, 103)
	3	180.0 (150, 200)	n.a.
Fluoroscopy time by no. of leaks, min	1	20 (14, 30)	17.5 (12, 27)
	2	25 (19, 35)	11.0 (9, 28)
	3	30 (20, 52)	n.a.
Success rates	Device success (at DO) <sup>p,z</sup>	88.9% [95% CI: 80.0%, 94.3%]	
	Procedural success (at DO) <sup>p,x</sup>	86.6% [95% CI: 77.4%, 92.5%]	
	Clinical success (at 6 months) <sup>l</sup>	86.5% [95% CI: 78.5%, 91.9%]	

Values are N (%), median (Q1, Q3) or mean±SD. Success rates are % [95% confidence interval]. \*The numbers may not add up to the column totals and the percentages may not add up to 100% because of missing data. In this table continuous data are given with at least 72.2% evaluable data points. <sup>y</sup>Patients in NYHA Class I/II or patients no longer dependent on blood transfusions at six months, who did not experience procedure- or device-related major complications. <sup>p</sup>Unit of analysis is patients with safety data available (N=136). <sup>x</sup>Device success and no procedure- or device-related major complications. <sup>z</sup>Unit of analysis is individual occluder. Multiple occluders may refer to a single patient. <sup>l</sup>Patients with stable implantation and paravalvular regurgitation reduced to ≤mild (small). DO: day of implantation; no.: number; PLD: paravalvular leak device; TEE: transoesophageal echocardiography; TTE: transthoracic echocardiography

**Table 3. Leak characteristics.**


		Mitral, n=131y*	Aortic, n=53y*
Maximum leak diameter	<5 [mm]	38 (33.0%)	10 (26.3%)
	5-10 [mm]	55 (47.8%)	22 (57.9%)
	>10-<15 [mm]	16 (13.9%)	3 (7.9%)
	≥15 [mm]	6 (5.2%)	3 (7.9%)
Shape of leak	Slit	2 (2.0%)	0 (0.0%)
	Oval	36 (36.7%)	6 (28.6%)
	Round	6 (6.1%)	1 (4.8%)
Location of leak	Anterior	17 (13.0%)	n.a.
	Lateral	29 (22.1%)	n.a.
	Medial	38 (29.0%)	n.a.
Location of leak	Posterior	47 (35.9%)	n.a.
	LCS	n.a.	11 (21.2%)
	NCS	n.a.	29 (55.8%)
Number of devices implanted per leak	RCS	n.a.	12 (23.1%)
	1	104 (88.9%)	36 (94.7%)
	2	12 (10.3%)	2 (5.3%)
	3	1 (0.9%)	0 (0.0%)

Values are N (%) or mean±SD. \* The numbers may not add up to the column totals and the percentages may not add up to 100% because of missing data. <sup>y</sup> Unit of analysis is individual leaks. Multiple leaks may refer to a single patient. LCS: left coronary sinus; NCS: non-coronary sinus; RCS: right coronary sinus


10.8%, small in 81.1% and absent in 5.4% (**Figure 4**). Overall, PVL improved from moderate/severe to no more than mild/small in 87.7% of ML patients and 86.5% of AL patients. One (0.7%) patient underwent repeat closure four months after the index procedure because of significant residual leak. The device success rate, defined as stable implantation and PV regurgitation reduction to <mild, was 88.9%.

NYHA class improved in most of the patients over a mean follow-up of 153±80 days. The proportion of patients in NYHA Class III/IV decreased from 86.8% at baseline to 11.4% at follow-up (**Figure 5**). The proportion of patients in need of haemolysis-related blood transfusion decreased from 36.8% to 5.9% and 8.3% to 0% in ML and AL patients, respectively. The laboratory values of a subset of patients are summarised in **Supplementary Figure 1**. The clinical success rate, defined as patients in NYHA Class I/II or no longer dependent on blood transfusions at six-month follow-up, was 86.5%. All-cause mortality was 7.4%. No death was associated with the device.


One (0.7%) patient with a small residual leak had recurrence of haemolytic anaemia requiring transient blood transfusions. In another case, intraprocedural TEE showed that PLD deployment blocked the movement of the prosthetic valve leaflets. The device was recaptured percutaneously without any complication and successfully replaced with a smaller PDL. Two intraprocedural embolisations occurred during delivery sheath placement for the



**Figure 3.** The Occlutech PLD types used for paravalvular leak closure with frequencies. Occlutech PLDs exist in two shapes (rectangular and square) and with two different types of connection between the proximal and distal disc (waist and twist). Frequencies are given. Unit of analysis is individual occluder.



**Figure 4.** Paravalvular regurgitation in the mitral and aortic patient populations before and six months following implantation. Wilcoxon signed-rank test has been applied. Fractions without percent value represent mitral leaks at BL (small [1.4%] and moderate [1.4%]) and at 6M (moderate [7.6%] and severe [4.5%]), and for aortic leaks at BL (no [0%] and moderate [8.1%]) and at 6M (no [5.4%] and severe [2.7%]). BL: baseline visit; 6M: six-month follow-up visit



**Figure 5.** NYHA functional classification in the mitral and aortic patient populations before and six months following implantation. Wilcoxon signed-rank test has been applied. Fractions without percent value represent mitral leaks at BL (Class I [1.5%]) and at 6M (Class IV [4.3%]), and for aortic leaks at BL (Class I [2.8%]) and at 6M (Class IV [2.8%]). BL: baseline visit; NYHA: New York Heart Association; 6M: six-month follow-up visit

deployment of an additional PLD. One embolisation was managed surgically and one with percutaneous retrieval. One late embolisation was detected at follow-up. Complications at the femoral puncture site occurred in 0.7%, bleeding complications in 2.9% and arrhythmias requiring treatment in 4.4% of the cases. In 66.7% of the patients, arrhythmias occurred during the procedure or hospital stay (Table 4).

**Table 4. Complications.**

	Mitral, N=92*	Aortic, N=44*
Device embolisation (surgically resolved)	1 (1.1%)	0 (0%)
Device embolisation (percutaneously resolved)	1 (1.1%)	0 (0%)
Late device embolisation	1 (1.1%)	0 (0%)
Interference with prosthetic valve leaflets (surgically resolved)	0 (0%)	0 (0%)
Interference with prosthetic valve leaflets (percutaneously resolved)	1 (1.1%)	0 (0%)
New-onset haemolytic anaemia requiring transfusions (transient)	1 (1.1%)	0 (0%)
Complication at femoral puncture site	1 (1.1%)	0 (0%)
Need for repeat procedure	1 (1.1%)	0 (0%)
Arrhythmias requiring treatment	5 (5.4%)	1 (2.3%)
Bleeding complication	3 (3.3%)	1 (2.3%)
Recurrent haemolytic anaemia	3 (3.3%)	0 (0%)
Valve surgeries	2 (2.2%)	1 (2.3%)
Cardiac resynchronisation therapy	1 (1.1%)	0 (0%)
Death following surgical valve replacement	1 (1.1%)	0 (0%)
Sudden unexplained death	1 (1.1%)	0 (0%)
Stroke death (1 haemorrhagic, 1 ischaemic)	2 (2.2%)	0 (0%)
Death (disease-related)	4 (4.3%)	2 (4.5%)
All-cause mortality	8 (8.7%)	2 (4.5%)
Values are N (%). * Unit of analysis is patients with safety data available (SAF population).		

## Discussion

The performance endpoint of this study was effective PVL closure, defined as a stable implantation and PVL reduction to no more than mild. The study met this endpoint in 88.9% of the patients. These results compare favourably with those of previous studies, which showed technical success rates ranging between 62%<sup>9</sup> and 87%<sup>10</sup>. In 87.3% of our study patients, PVL was mild or no longer detectable at six-month echocardiography follow-up. This result is of utmost importance as several studies have shown a direct correlation between the grade of residual regurgitation and the rate of repeat intervention and survival<sup>3,11-13</sup>. In line with the technical success observed, PVL closure was associated with significant clinical improvement and reduction of the need for blood transfusion.

As with every interventional technique, transcatheter PVL closure is not free from potential complications<sup>14,15</sup>. Device malpositioning or embolisation has been reported in 1% to 5% of large series<sup>12,16</sup>. The main causes are frail tissue around the valve, multiple device deployment and complicated access to PVL combined with imaging limitations. Generally, in such cases, snaring and recapture of the device into the delivery sheath can be performed. Only one (0.7%) embolisation requiring surgery was reported in our registry.

Interference on prosthetic valve leaflet function is a feared complication of percutaneous PVL closure. It is not rare: clinical studies report rates ranging from 3.6%<sup>3</sup> to 5%<sup>16,17</sup>. In our registry, this occurred in one (0.7%) patient only. Importantly, interference occurred during the procedure and before device release. The very low rate of valve interference may be attributed to the unique design of the PLD, whose concavities of the four edges produce only minimal overlapping with the surgical valve. Undoubtedly, careful image-based assessment of PVL anatomy is of utmost importance for choosing the right size of device and for ensuring the proper apposition of the device disc to the surrounding tissue with full sealing<sup>18</sup>.

Of note, oversized devices might also have the opposite effect and increase the regurgitant defect.

Regurgitation through a residual leak or the PLD has an important impact on clinical outcome. Indeed, it can be associated with persistent or new haemolysis. We observed new haemolytic anaemia in one (0.7%) patient and recurrence of haemolytic anaemia in 2.2% of the patients. In two additional patients, who underwent successful PVL closure for haemolytic anaemia, transfusion dependency was reduced but not completely avoided. With a moderate or severe residual leak observed in 12.1% of the ML patients and 13.5% of the AL patients, the Occlutech PLD compares favourably with other devices for which moderate or severe residual leaks were reported in 11% to 24% of the cases<sup>3,11</sup>. A repeat procedure was needed in one (0.7%) patient only, a rate lower than that (6%) reported by Calvert et al<sup>19</sup>.

Most of our patients showed clinical benefits, as indicated by a significant improvement of NYHA class and a significant reduction of haemolytic anaemia and haemolysis-related blood transfusions.

It must be emphasised that the percutaneous PVL closure procedure is performed mostly in high-risk patients for whom repeat surgery is not suitable. Accordingly, most patients with PVL have multiple comorbidities, underlining the need for a less invasive procedure. Indeed, the all-cause mortality rate of 7.4% observed in our registry is comparable to that observed in the literature<sup>3,19</sup> and may be explained by the high-risk characteristics of the patients. It should be noted that a significant improvement in procedural outcomes has been reported with increasing operator experience<sup>12</sup>, underlining the importance of the learning curve associated with this complex procedure, which requires commitment and a wide variety of interventional skills.

In summary, the choice of an appropriate occluder device along with thorough preprocedural planning using advanced imaging modalities (specifically fusion imaging) and alternative access approaches (transapical “hybrid technique”) are critical for achieving a high intraprocedural success rate and for reducing major adverse events of this transcatheter procedure.

## Study limitations

This is a retrospective registry. Therefore, there is a theoretical bias associated with such an investigation. There was no evaluation of TEE by a central core laboratory, nor was an audit of the records performed. Having many different centres and investigators with different skills and techniques participating in the study increases the complexity of comparison of the implantation methods used. Finally, there was no control group comparing this treatment to surgery.

## Conclusions

Transcatheter PVL closure with a specifically designed PLD demonstrated effectiveness with a relatively low rate of major complications. Procedural success for ML and AL closure was high, with a low rate of residual or recurrent leaks, and was associated with significant improvement in NYHA class and reduction of haemolytic anaemia and transfusion dependency. However, further data are needed to assess the clinical outcome of patients treated with this device at longer-term follow-up.

## Impact on daily practice

Paravalvular leak is an important complication of valve replacement surgery and is associated with significant morbidity and mortality. For high-risk symptomatic PVL patients, catheter closure is a viable therapeutic alternative strategy to surgical PVL repair and may represent a first-line treatment. Transcatheter PVL closure with the specifically designed Occlutech PLD occluder was demonstrated to be an effective procedure with a relatively low rate of serious complications.

## Acknowledgements

The authors would like to acknowledge all participating investigators who are listed in **Supplementary Appendix 1** for making it possible to perform this international study. The authors express their appreciation to Simon Kordowich and Thomas Schöndorf for providing statistical support.

## Conflict of interest statement

E.M. Onorato is a consultant for Occlutech. The other authors have no conflicts of interest to declare.

## References

1. Hourihan M, Perry SB, Mandell VS, Keane JF, Rome JJ, Bittl JA, Lock JE. Transcatheter umbrella closure of valvular and paravalvular leaks. *J Am Coll Cardiol.* 1992;20:1371-7.

2. Cruz-Gonzalez I, Rama-Merchan JC, Rodríguez-Collado J, Martín-Moreiras J, Diego-Nieto A, Barreiro-Pérez M, Sánchez PL. Transcatheter closure of paravalvular leaks: state of the art. *Neth Heart J.* 2017;25:116-24.

3. Sorajja P, Cabalka AK, Hagler DJ, Rihal CS. Long-term follow-up of percutaneous repair of paravalvular prosthetic regurgitation. *J Am Coll Cardiol.* 2011;58:2218-24.

4. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, Leipsic J, Maisano F, Millan X, Nataf P, O’Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB; Paravalvular Leak Academic Research Consortium. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis. *Eur Heart J.* 2018;39:1224-45.

5. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, Khandheria BK, Levine RA, Marx GR, Miller FA Jr, Nakatani S, Quiñones MA, Rakowski H, Rodriguez LL, Swaminathan M, Waggoner AD, Weissman NJ, Zabalgoitia M; American Society of Echocardiography’s Guidelines and Standards Committee; Task Force on Prosthetic Valves; American College of Cardiology Cardiovascular Imaging Committee; Cardiac Imaging Committee of the American Heart Association; European Association of Echocardiography; European Society of Cardiology; Japanese Society of Echocardiography; Canadian Society of Echocardiography; American College of Cardiology Foundation; American Heart Association; European Association of Echocardiography; European Society of Cardiology; Japanese Society of Echocardiography; Canadian Society of Echocardiography. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography’s Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. *J Am Soc Echocardiogr.* 2009;22:975-1014.

6. Zorinas A, Janusauskas V, Davidavicius G, Puodziukaite L, Zakarkaite D, Kramena R, Čypienė R, Bilkis V, Rucinskas K, Aidietis A, Onorato E. Fusion of real-time 3D transesophageal echocardiography and cardiac fluoroscopy imaging in transapical catheter-based mitral paravalvular leak closure. *Postepy Kardiol Interwencyjne.* 2017;13:263-8.

7. Onorato EM, Zorinas A, Janusauskas V, Davidavicius G, Zakarkaite D, Kramena R, Bilkis V, Rucinskas K, Samalavicius RS, Aidietis A. Chapter 4. Occlutech® Paravalvular Leak Device (PLD). In: Smolka G, Wojakowski W, Tendera M, Editors. *Transcatheter Paravalvular Leak Closure.* Singapore: Springer Nature Singapore Pte Ltd.; 2017. pp 55-77.

8. Goktekin O, Vatankulu MA, Ozhan H, Ay Y, Ergelen M, Tasal A, Aydin C, Ziya I, Ates I, Hijazi Z. Early experience of percutaneous paravalvular leak closure using a novel Occlutech occluder. *EuroIntervention.* 2016;11:1195-200.

9. Reed GW, Tuzcu EM, Kapadia SR, Krishnaswamy A. Catheter-based closure of paravalvular leak. *Expert Rev Cardiovasc Ther.* 2014;12:681-92.

10. García E, Arzamendi D, Jimenez-Quevedo P, Sarnago F, Martí G, Sanchez-Recalde A, Lasa-Larraya G, Sancho M, Iñiguez A, Goicolea J, Garcia-San Roman K, Alonso-Briales JH, Molina E, Calabuig J, Freixa X, Berenguer A, Valdes-Chavarri M, Vazquez N, Diaz JF, Cruz-Gonzalez I. Outcomes and predictors of success and complications for paravalvular leak closure: an analysis of the Spanish realWorld paravalvular LEaks closure (HOLE) registry. *EuroIntervention.* 2017;12:1962-8.

11. Sorajja P, Cabalka AK, Hagler DJ, Rihal CS. Percutaneous repair of paravalvular prosthetic regurgitation: acute and 30-day outcomes in 115 patients. *Circ Cardiovasc Interv.* 2011;4:314-21.



12. Noble S, Jolicoeur EM, Basmadjian A, Levesque S, Nozza A, Potvin J, Crépeau J, Ibrahim R. Percutaneous paravalvular leak reduction: procedural and long-term clinical outcomes. *Can J Cardiol*. 2013;29:1422-8.
13. Alkhouli M, Zack CJ, Sarraf M, Eleid MF, Cabalka AK, Reeder GS, Hagler DJ, Maalouf JF, Nkomo VT, Rihal CS. Successful Percutaneous Mitral Paravalvular Leak Closure is Associated With Improved Midterm Survival. *Circ Cardiovasc Interv*. 2017 Dec;10(12).
14. Angulo-Llanos R, Sarnago-Cebada F, Corrales JE, Gutierrez-Ibanes E, Fernandez-Aviles F. Two-Year Follow Up After Surgical Versus Percutaneous Paravalvular Leak Closure: A Non-Randomized Analysis. *Catheter Cardiovasc Interv*. 2016;88:626-34.
15. Ruiz CE, Jelmin V, Kronzon I, Dudy Y, Valle-Fernandez RD, Einhorn BN, Chiam PT, Martinez C, Eiros R, Roubin G, Cohen HA. Clinical outcomes in patients undergoing percutaneous closure of periprosthetic paravalvular leaks. *J Am Coll Cardiol*. 2011;58:2210-7.
16. Yuan SM, Shinfeld A, Raanani E. Displacement of the Amplatzer occluder device from the mitral paraprosthesis leak. *Interact Cardiovasc Thorac Surg*. 2008;7:1131-3.
17. Alkhouli M, Sarraf M, Maor E, Sanon S, Cabalka A, Eleid MF, Hagler DJ, Pollak P, Reeder G, Rihal CS. Techniques and Outcomes of Percutaneous Aortic Paravalvular Leak Closure. *JACC Cardiovasc Interv*. 2016;9:2416-26.
18. Smolka G, Pysz P, Kozłowski M, Jasiński M, Gocoł R, Roleder T, Kargul A, Ochała A, Wojakowski W. Transcatheter closure of paravalvular leaks using a paravalvular leak device – a prospective Polish registry. *Postępy Kardiologii Interwencyjnej*. 2016;12:128-34.
19. Calvert P, Northridge D, Malik I, Shapiro L, Ludman P, Qureshi S, Mullen M, Henderson R, Turner M, Been M, Walsh KP, Casserly I, Morrison L, Walker NL, Thomson J, Spence MS, Mahadevan VS, Hoye A, MacCarthy PA, Daniels MJ, Clift P, Davies WR, Adamson PD, Morgan G, Aggarwal SK, Ismail Y, Ormerod JO, Khan HR, Chandran SS, de Giovanni J, Rana BS, Ormerod O, Hildick-Smith D. Percutaneous Device Closure of Paravalvular Leak: Combined

Experience From the United Kingdom and Ireland. *Circulation*. 2016;134:934-44.

## Supplementary data

**Supplementary Appendix 1.** Participating centres and investigators.

**Supplementary Figure 1.** Changes relative to baseline in laboratory values and blood cell counts at six months following implantation.

**Moving image 1.** 2D TEE colour Doppler showing a significant regurgitant jet through a mitral paravalvular leak.

**Moving image 2.** 3D TEE colour Doppler showing an anterolateral (9-11 o'clock) mitral paravalvular leak.

**Moving image 3.** Real-time 3D TEE showing the crescent shape of the mitral leak at 9-11 o'clock.

**Moving image 4.** Fluoroscopic (A) and real-time 3D TEE showing the catheter crossing the leak (arrows) from a transapical approach.

**Moving image 5.** Procedural fluoroscopic steps of the PVL closure procedure using a 12×5 mm rectangular waist paravalvular leak device (PLD). A) Distal disc opening; B) waist and proximal disc opening; C) stability test ("pull & push"); D) 12×5 mm PLD *in situ*.

**Moving image 6.** 3D TEE colour Doppler in two different views showing final position of the occluder device.

The supplementary data are published online at:  
<https://eurointervention.pronline.com/doi/10.4244/EIJ-D-19-00517>



## Supplementary data

### Supplementary Appendix 1. Participating centres and investigators

**Italy:** Centro Cardiologico Monzino, IRCCS, Università degli Studi di Milano (Prof. A.L. Bartorelli, Dr E.M. Onorato, Prof. F. Alamanni, Dr M. Pepi, Dr G. Tamborini, Dr M. Muratori); Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria (Dr M. Reale, Dr M. Vercellino, Dr A.M. Costante, Dr G. Pistis, Dr D. Mercogliano, Dr C. Cavoza, Dr A. Audo); USVD Emodinamica, Spedali Civili di Brescia (Dr F. Etori, Dr S. Curello, Dr G. Chizzola, Dr E. Chiari); Clinica Montevergine, Mercogliano (Av) (Dr T. Tesorio, Dr M. Agrusta, Dr A. Cioppa, Dr L. Salemme, Dr G. Popusoi, Dr A. Santoro, Dr C. Zebele); Humanitas Gavazzeni, Bergamo (Dr A. Piti, Dr F. Santoro, Dr M. Pennesi); Clinica San Michele, Maddaloni (Dr A. De Bellis, Dr P. Landino, Dr A. Caruso, Dr G. Valva, Dr V. Ambrosini); Clinica San Gaudenzio, Novara (Dr G. Martinelli, Dr G. Cerin, Dr G. Carosio, Dr M. Diena); Città di Alessandria, Policlinico di Monza (Dr M. Fabbrocini, Dr P. Cioffi); Dipartimento di Malattie Cardiovascolari, Campobasso (Dr C.M. De Filippo, Dr P. Spatuzza, Dr E. Caradonna).

**Poland:** Medical University of Silesia, Katowice, Poland (Dr G. Smolka, Dr Pysz, Dr Kozłowski, Prof. Wojakowski).

**Lithuania:** Santariskiu Klinikos, Vilnius (Prof. A. Aidietis, Dr A. Zorinas, Dr V. Janusauskas, Dr K. Rucinskas, Dr D. Zakarkaite, Dr R. Kramena, Dr V. Bilkis).

**France:** Centre Hospitalier Universitaire, “Charles Nicolle” Rouen (Prof P-Y. Litzer, Prof H. Eltchaninoff, Dr M. Godin, Dr F. Bauer, Prof. F. Doguet); Centre Hospitalier Universitaire, Hôpital Arnaud de Villeneuve, Montpellier (Prof. B. Albat, Dr T. Gandet, Dr J.C. Macia, Dr F. Cransac); Centre Hospitalier Régional Universitaire, Lille (Prof. F. Godart, Prof. F. Juthier).


**Hungary:** National Heart Center, Budapest (Prof. A. Szatmari, Dr G. Fontos); Semmelweis University School of Medicine (Prof. B. Merkely, Dr A. Apor, Dr M. Levente, Dr L. Gellér).

**Kazakhstan:** National Research Cardiac Surgery Center, Astana (Dr A. Mussayev, Dr S. Almazovich Alimbaev, Prof. Y. Pya).

**Cyprus:** American Heart Institute, Nicosia (Dr C.P. Christos, Dr S. Constantinides, Dr M. Neofytou).

**Morocco:** Centre des Maladies du Coeur, Clinique Al Kawtar – Fés (Dr. O. Fassi Firh).

**Romania:** Centru Cardiovascular Monza, Bucharest (Prof. S. Balanescu, Dr A. Linte).



**Supplementary Figure 1.** Changes relative to baseline in laboratory values and blood cell counts at six months following implantation.

N is given per value. Wilcoxon signed-rank test has been applied and \* indicates p-values < 0.05.

ERY: erythrocytes; HGB: haemoglobin; LDH: lactate dehydrogenase; LEU: leucocytes; NT ProBNP:

N-terminal prohormone of brain natriuretic peptide; THR: thrombocytes